胸腺肽对慢阻肺急性加重期的疗效及T淋巴细胞亚群的影响

目的探讨胸腺肽对慢性阻塞性肺疾病急性加重期的疗效及T淋巴细胞亚群的影响。方法将2013年5月至2015年5月医院收治的70例急性加重期慢阻肺患者按照随机数字表法分为治疗组35例和对照组35例,对照组采用常规治疗,治疗组在对照组基础上静脉滴注胸腺肽,两组患者均治疗10天为1个疗程。比较两组患者治疗前后临床特征、生活质量、动脉血气指标,并分析治疗前后血清白细胞介素-8(interleukin-8,IL-8)、C反应蛋白(C-reactive protein,CRP)、肿瘤坏死因子(tumor necrosis factors-α,TNF-α)及外周血T淋巴细胞亚群。结果治疗1个疗程后,治疗组总有效率为97.2%,对照组为82.9%,治疗组总有效率显著高于对照组(χ~2=3.968,P=0.046)。两组患者治疗后临床症状、生活质量评分均显著降低,PaO_2、FEV1、FEV1/FVC均显著升高,Pa CO2显著降低,与治疗前比较差异具有统计学意义(P0.05);治疗后治疗组临床症状、生活质量评分显著低于对照组,PaO_2、FEV1、FEV1/FVC显著高于对照组,PaCO_2显著显著低于对照组(P0.05)。治疗后两组患者血清IL-8、CRP、TNF-α、CD_8~+显著降低,CD_4~+、CD_4~+/CD_8~+显著升高,与治疗前比较差异具有统计学意义(P0.05);治疗后治疗组血清IL-8、CRP、TNF-α、CD+8显著低于对照组,CD_4~+、CD_4~+/CD_8~+显著高于对照组(P0.05)。结论胸腺肽能够提高慢阻肺急性加重期的临床疗效,降低血清细胞因子水平、改善外周血T淋巴细胞亚群。

Clinical effect of thymosin in treatment with AECOPD patients and its influence on T lymphocyte subsets

Objective To explore the clinical effect of thymosin in treatment with AECOPD patients and its influence on T lymphocyte subsets. Methods A total of 70 AECOPD patients from May 2013 to May 2015 were ran-domly divided into the treatment group(35 cases)and the control group(35 cases). The control group was treated with conventional therapy, and the treatment group was additionally given intravenous thymosin. The treatment course was 10 days. Their clinical features, quality of life and arterial blood gas index were recorded before and after treat-ment, and interleukin-8, C-reactive protein, tumor necrosis factors-αand peripheral blood T lymphocyte subsets were analyzed between the two groups. Results The total effective rate was 97. 2% in the treatment group and 82. 9% in the control group(χ2 =3. 968, P=0. 046). After the treatment, their clinical symptoms and quality of life score were significantly lower, and the levels of PaO2 , FEV1 and FEV1/FVC were significantly higher in the treatment group than in the control group(P<0. 05). After the treatment, the serum levels of IL-8, CRP, TNF-α, and CD8+decreased significantly, and CD4+, CD4+ /CD8+ increased significantly in the two groups(P<0. 05), and the differ-ence was more pronounced in the treatment group than in the control group(P<0. 05). Conclusion Thymosin has better clinical curative effect in the treatment of AECOPD patients, which can reduce the serum level of cytokines and improve the peripheral blood T lymphocyte subsets.